Microbiome Diagnostics Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global microbiome diagnostics market growth forecasted to transform from $146 million in 2023 to $300 million by 2028, driven by a CAGR of 15.5%. Market growth is driven by the rising incidence of chronic diseases, collaborative efforts between microbiome industry and academic institutes, and growing demand of personalized medicine.

Attractive Opportunities in the Microbiome Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Microbiome Diagnostics Market Dynamics

DRIVER: Collaborative efforts between the microbiome industry and academia for microbiome research

The human microbiome is a rapidly growing field of research, and there has been a significant surge in industry-academia collaborations centered around microbiome research. These collaborations unite academic researchers and industry partners to develop novel microbiome-based diagnostic products, as well as to enhance our understanding of the microbiome’s role in health and disease.

Overall, the increasing number of industry-academia collaborations focused on microbiome research propels the development of the field. These provide opportunities for the development of new microbiome-based diagnostic products and facilitate the translation of basic research findings into clinical applications. These collaborations also help bridge the gap between academia and the microbiome industry, bringing together different areas of expertise and resources to enhance our understanding of the human microbiome.

RESTRAINTS: End-user budget constraints in developing countries

In developing countries, academic R&D is mostly dependent on external funding. NGS technology is mostly used for microbiome analysis. Despite continuous efforts by governments and private bodies to provide funds for research across the globe, various research and academic institutes face budget constraints regarding the purchase and use of advanced and premium-priced equipment and technologies. Although the price of NGS sequencing has declined, NGS sequencers continue to be costly.

OPPORTUNITY: Increased collaboration of key players and small innovative companies to work on new microbiome technologies

With several small innovative players operating in the market, there are various high-growth opportunities for key stakeholders to buy out companies to study microbiomes in the hope of identifying various microbiome diagnostic kits, biomarkers targets for various indications, such as obesity, liver disorders, diabetes, and metabolic disorders. Many market leaders focus on strategic collaborations and partnerships to increase their product pipelines with well-organized research and development techniques. In the last two years, there have been several collaborations and partnerships involving major companies.

CHALLENGE: Adverse impact of complex regulatory policies on commercialization of microbiome

The commercialization of microbiomes is a complex process impacted by a range of regulatory policies and guidelines. These policies are implemented to ensure the safety and efficacy of microbiome-based products and services, but they can also create significant barriers to commercialization and growth in the microbiome-based diagnostics market.

Microbiome Diagnostics Market Ecosystem/Market Map

In 2022, kits and reagents accounted for the largest share in the microbiome diagnostics industry, by product.

The microbiome diagnostics market is segmented into kits & reagents, and instruments. Kits & reagents accounted for the largest share of the microbiome-based diagnostics market in 2022 by product. The repeat purchases and consumption of kits and reagents for diagnostic procedures as compared to the instruments, which have a longer shelf time and can be used for multiple procedures, is expected to contribute to the significant share of the technology segment.

In 2022, fecal segment accounted for the largest share in the microbiome diagnostics industry, by sample.

Based on sample, the microbiome diagnostics market is segmented into fecal, saliva, skin and other samples. In 2022, fecal accounted for the largest share of the microbiome diagnostics market, by sample. The increasing incidences of diseases, and increasing demand for personalized medicine will drive the market growth.

In 2022, hospitals accounted for the largest share in the microbiome diagnostics industry, by end user.

The microbiome diagnostics market is segmented into academic and research institutes, hospitals, pharmaceutical and biotechnology companies and other end users. Hospitals accounted for the largest share of the microbiome-based diagnostics market by end user. The share of the end-user segment is owing to the rising incidence of diseases such as metabolic disorders, gastrointestinal diseases etc.

In 2022, North America accounted for the largest share of the microbiome diagnostics industry.

The global microbiome diagnostics market is segmented into five major regions: North America, Europe, the Asia Pacific, Rest of the World. North America accounted for the largest share of the microbiome-based diagnostics market in 2022. The increasing incidences of diseases, the collaboration between microbiome research and academic institutes for microbiome research, growing demand for personalized medicine in the region contribute to this regional segment’s large share.

To know about the assumptions considered for the study, download the pdf brochure

The major players in microbiome diagnostics market are DNA Genotek (Canada), Genetic Analysis AS (Norway), and Microba Life Sciences (US). These players’ market leadership is due to their broad product portfolios and vast global footprint. These dominant market players have advantages, including strong research and development budgets, better marketing and distribution networks, and established brand recognition.

Scope of the Microbiome Diagnostics Industry

This report categorizes the microbiome diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Reagents & Kits
• Instruments

By Technology

• 16S rRNA Sequencing
• Shot Gun Metagenomics
• Metatranscriptomics
• Other Technology

By Sample

• Feces
• Saliva
• Skin
• Other Sample

By Application

• Disease Diagnostics Application
  • Gastrointestinal Disorders
  • Metabolic Diseases
  • Other Application
• Research Application

By End User

• Hospitals
• Academic and Research Institutes
• Biotechnology and Pharmaceutical Companies

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Rest of the World

Recent Developments of Microbiome Diagnostics Industry:

• In 2023, The Genetic Analysis (Norway) entered into an agreement with Eagle Biosciences Inc. (US) through its distributors with an undisclosed partner. A high-volume lab company providing laboratory diagnostics to clinics, public health departments and research universities in the US.
• In 2022, DNA Genotek (Canada) Launched OMNIgene GUT OMR-205. This product allows for the stabilization, self-collection, storage and transportation of both microbial DNA and RNA at ambient temperature for gut microbiome profiling.
• In 2022, Genetic Analysis (Norway) company entered into an agreement with Microbiome Research Pvt. Ltd. to launch GA-map technology in India.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst